Market Intelligence

From new FDA guidance and community engagement efforts to the challenges of precision medicine and decentralization, In Vivo spoke with industry experts about racial and ethnic diversity in the context of clinical trials.

A selection of articles you might have missed from November 2022, during which In Vivo shone the spotlight on the Asia Pacific region.

With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.

Pharmaceutical supply chains may grow less efficient and less risk prone as US government gets more involved to ensure availability of pandemic and essential medicines. But what about pediatric oncology medicines and other treatments that save lives even though they may not be considered essential?

Immuno-oncology therapies have revolutionized the treatment of many cancers over the last decade. This period has also witnessed a dramatic growth in China’s domestic pharmaceutical industry, and significant changes in the interaction between this industry and international pharma. This coalescence has led to excitement about the role that Chinese IO could play on the global stage, tempered by regulatory set-backs and revised marketing timelines. 

Two $1bn+ alliances were penned in October. Financing reached $7.7bn in biopharma, $636m in device, and $140m in diagnostics.

Ripples from the COVID-19 pandemic can be felt across Asia Pacific as investment from foreign firms into the region dropped by 45% from 2019 to 2020, and continued its decline in 2021 to 34%.

During Q3, biopharmas brought in an aggregate $18.1bn in financing and device company fundraising totaled $5.1bn; while in vitro diagnostic firms and research tools players raised $771m.

Sweden is a European leader in the life sciences and now has its sights set on becoming a global force in digital and e-health. A rich academic tradition, strong manufacturing infrastructure and health care as a pillar of its unique Mixed Economy make Sweden an attractive home for pharma, biotech and medtech companies and a target for investors.

Recent patent extension win for Januvia illustrates the dilemma that will be faced by manufacturers of older, single-source drugs that are chosen for price negotiation in the Medicare program.

Just one $1bn+ alliance was penned in September compared to eight that were signed in August.

PVC, the most used polymer in the manufacture of single-use medical devices, has always been a target for the environmental lobby. The rise of the green agenda has heightened sensitivities further still. Europe’s PVC MedAlliance aims to show how the substance can fit into sustainability programs.